The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
 

Editor

Share

Personal info

View

Links

Table of contents

About

Terms

 

Edith A. Perez

Division of Hematology and Oncology

College of Medicine

Mayo Clinic

Jacksonville

Florida

[email]@mayo.edu

Name/email consistency: high

 
 
 
 
 
 
 

Affiliations

  • Division of Hematology and Oncology, College of Medicine, Mayo Clinic, Jacksonville, Florida. 1998 - 2012
  • Mayo Clinic, 4500 San Pablo Rd, Jacksonville, FL 32224;. 1998 - 2011
  • Multidisciplinary Breast Clinic and Breast Cancer Program, Mayo Clinic, Jacksonville, FL 32224, USA. 2004 - 2010
  • Serene M. and Frances C. Durling Professor of Medicine, Mayo Clinic, 4500 San Pablo Rd, Jacksonville, USA. 2010
  • Mayo Clinic, Jacksonville, USA. 2007
  • St Michael's Hospital, Toronto, Canada. 2006
  • Mayo Clinic and Mayo Foundation, Rochester, USA. 2002 - 2005

References

  1. Current and emerging targeted therapies for metastatic breast cancer. Perez, E.A., Spano, J.P. Cancer (2012) [Pubmed]
  2. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. Perez, E.A., Suman, V.J., Davidson, N.E., Gralow, J.R., Kaufman, P.A., Visscher, D.W., Chen, B., Ingle, J.N., Dakhil, S.R., Zujewski, J., Moreno-Aspitia, A., Pisansky, T.M., Jenkins, R.B. J. Clin. Oncol. (2011) [Pubmed]
  3. Four-Year Follow-Up of Trastuzumab Plus Adjuvant Chemotherapy for Operable Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Joint Analysis of Data From NCCTG N9831 and NSABP B-31. Perez, E.A., Romond, E.H., Suman, V.J., Jeong, J.H., Davidson, N.E., Geyer, C.E., Martino, S., Mamounas, E.P., Kaufman, P.A., Wolmark, N. J. Clin. Oncol. (2011) [Pubmed]
  4. Breast cancer management: opportunities and barriers to an individualized approach. Perez, E.A. Oncologist (2011) [Pubmed]
  5. Efficacy of ixabepilone in ER/PR/HER2-negative (triple-negative) breast cancer. Perez, E.A., Patel, T., Moreno-Aspitia, A. Breast Cancer Res. Treat. (2010) [Pubmed]
  6. North Central Cancer Treatment Group (NCCTG) N0432: phase II trial of docetaxel with capecitabine and bevacizumab as first-line chemotherapy for patients with metastatic breast cancer. Perez, E.A., Hillman, D.W., Dentchev, T., Le-Lindqwister, N.A., Geeraerts, L.H., Fitch, T.R., Liu, H., Graham, D.L., Kahanic, S.P., Gross, H.M., Patel, T.A., Palmieri, F.M., Dueck, A.C. Ann. Oncol. (2010) [Pubmed]
  7. HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. Perez, E.A., Reinholz, M.M., Hillman, D.W., Tenner, K.S., Schroeder, M.J., Davidson, N.E., Martino, S., Sledge, G.W., Harris, L.N., Gralow, J.R., Dueck, A.C., Ketterling, R.P., Ingle, J.N., Lingle, W.L., Kaufman, P.A., Visscher, D.W., Jenkins, R.B. J. Clin. Oncol. (2010) [Pubmed]
  8. Adjuvant therapy of triple negative breast cancer. Perez, E.A., Moreno-Aspitia, A., Aubrey Thompson, E., Andorfer, C.A. Breast Cancer Res. Treat. (2010) [Pubmed]
  9. Impact, mechanisms, and novel chemotherapy strategies for overcoming resistance to anthracyclines and taxanes in metastatic breast cancer. Perez, E.A. Breast Cancer Res. Treat. (2009) [Pubmed]
  10. Microtubule inhibitors: Differentiating tubulin-inhibiting agents based on mechanisms of action, clinical activity, and resistance. Perez, E.A. Mol. Cancer Ther. (2009) [Pubmed]
  11. Trastuzumab. Perez, E.A., Palmieri, F.M., Brock, S.M. Cancer Treat. Res. (2009) [Pubmed]
  12. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. Perez, E.A., Suman, V.J., Davidson, N.E., Sledge, G.W., Kaufman, P.A., Hudis, C.A., Martino, S., Gralow, J.R., Dakhil, S.R., Ingle, J.N., Winer, E.P., Gelmon, K.A., Gersh, B.J., Jaffe, A.S., Rodeheffer, R.J. J. Clin. Oncol. (2008) [Pubmed]
  13. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Perez, E.A., Koehler, M., Byrne, J., Preston, A.J., Rappold, E., Ewer, M.S. Mayo Clin. Proc. (2008) [Pubmed]
  14. Cardiac toxicity of ErbB2-targeted therapies: what do we know? Perez, E.A. Clin. Breast Cancer (2008) [Pubmed]
  15. Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. Perez, E.A., Lerzo, G., Pivot, X., Thomas, E., Vahdat, L., Bosserman, L., Viens, P., Cai, C., Mullaney, B., Peck, R., Hortobagyi, G.N. J. Clin. Oncol. (2007) [Pubmed]
  16. Safety profiles of tamoxifen and the aromatase inhibitors in adjuvant therapy of hormone-responsive early breast cancer. Perez, E.A. Ann. Oncol. (2007) [Pubmed]
  17. Novel enhanced delivery taxanes: an update. Perez, E.A. Semin. Oncol. (2007) [Pubmed]
  18. Safety of aromatase inhibitors in the adjuvant setting. Perez, E.A. Breast Cancer Res. Treat. (2007) [Pubmed]
  19. HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial. Perez, E.A., Suman, V.J., Davidson, N.E., Martino, S., Kaufman, P.A., Lingle, W.L., Flynn, P.J., Ingle, J.N., Visscher, D., Jenkins, R.B. J. Clin. Oncol. (2006) [Pubmed]
  20. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. Perez, E.A., Josse, R.G., Pritchard, K.I., Ingle, J.N., Martino, S., Findlay, B.P., Shenkier, T.N., Tozer, R.G., Palmer, M.J., Shepherd, L.E., Liu, S., Tu, D., Goss, P.E. J. Clin. Oncol. (2006) [Pubmed]
  21. Aromatase inhibitors and bone loss. Perez, E.A., Weilbaecher, K. Oncology (Williston Park, N.Y.) (2006) [Pubmed]
  22. Appraising adjuvant aromatase inhibitor therapy. Perez, E.A. Oncologist (2006) [Pubmed]
  23. Phase II trial of dolastatin-10 in patients with advanced breast cancer. Perez, E.A., Hillman, D.W., Fishkin, P.A., Krook, J.E., Tan, W.W., Kuriakose, P.A., Alberts, S.R., Dakhil, S.R. Invest. New. Drugs (2005) [Pubmed]
  24. A phase II trial of docetaxel and carboplatin as first-line chemotherapy for metastatic breast cancer: NCCTG study N9932. Perez, E.A., Suman, V.J., Fitch, T.R., Mailliard, J.A., Ingle, J.N., Cole, J.T., Veeder, M.H., Flynn, P.J., Walsh, D.J., Addo, F.K. Oncology (2005) [Pubmed]
  25. Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Perez, E.A., Suman, V.J., Rowland, K.M., Ingle, J.N., Salim, M., Loprinzi, C.L., Flynn, P.J., Mailliard, J.A., Kardinal, C.G., Krook, J.E., Thrower, A.R., Visscher, D.W., Jenkins, R.B. Clin. Breast Cancer (2005) [Pubmed]
  26. Nanoparticle albumin-bound paclitaxel (ABI-007): a newer taxane alternative in breast cancer. Moreno-Aspitia, A., Perez, E.A. Future. Oncology. (london,. England) (2005) [Pubmed]
  27. Clinical cardiac tolerability of trastuzumab. Perez, E.A., Rodeheffer, R. J. Clin. Oncol. (2004) [Pubmed]
  28. Gemcitabine and platinum combinations in patients with breast cancer previously treated with anthracyclines and/or taxanes. Perez, E.A. Clin. Breast Cancer (2004) [Pubmed]
  29. Phase II study of oral etoposide and intravenous paclitaxel in extensive-stage small cell lung cancer. Perez, E.A., Geoffroy, F.J., Hillman, S., Johnson, E.A., Farr, G.H., Tazelarr, H.D., Hatfield, A.K., Krook, J.E., Maillard, J.A., Levitt, R., Marks, R.S. Lung. Cancer (2004) [Pubmed]
  30. Randomized phase II study of two irinotecan schedules for patients with metastatic breast cancer refractory to an anthracycline, a taxane, or both. Perez, E.A., Hillman, D.W., Mailliard, J.A., Ingle, J.N., Ryan, J.M., Fitch, T.R., Rowland, K.M., Kardinal, C.G., Krook, J.E., Kugler, J.W., Dakhil, S.R. J. Clin. Oncol. (2004) [Pubmed]
  31. Effect of doxorubicin plus cyclophosphamide on left ventricular ejection fraction in patients with breast cancer in the North Central Cancer Treatment Group N9831 Intergroup Adjuvant Trial. Perez, E.A., Suman, V.J., Davidson, N.E., Kaufman, P.A., Martino, S., Dakhil, S.R., Ingle, J.N., Rodeheffer, R.J., Gersh, B.J., Jaffe, A.S. J. Clin. Oncol. (2004) [Pubmed]
  32. Carboplatin in combination therapy for metastatic breast cancer. Perez, E.A. Oncologist (2004) [Pubmed]
  33. Management recommendations for adjuvant systemic breast cancer therapy. Perez, E.A. Breast. Dis (2004) [Pubmed]
  34. Adjuvant therapy approaches to breast cancer: should taxanes be incorporated?. Perez, E.A. Curr. Oncol. Rep (2003) [Pubmed]
  35. Phase I trial of high-dose tamoxifen in combination with cisplatin in patients with lung cancer and other advanced malignancies. Perez, E.A., Gandara, D.R., Edelman, M.J., O'Donnell, R., Lauder, I.J., DeGregorio, M. Cancer Invest. (2003) [Pubmed]
  36. Adjuvant therapy trials of radiotherapy and systemic treatment for breast cancer. Mincey, B.A., Vallow, L.A., Perez, E.A. Curr. Oncol. Rep (2002) [Pubmed]
  37. Weekly paclitaxel in women age 65 and above with metastatic breast cancer. Perez, E.A., Vogel, C.L., Irwin, D.H., Kirshner, J.J., Patel, R. Breast Cancer Res. Treat. (2002) [Pubmed]
  38. A randomized phase II study of sequential docetaxel and doxorubicin/cyclophosphamide in patients with metastatic breast cancer. Perez, E.A., Geeraerts, L., Suman, V.J., Adjei, A.A., Baron, A.T., Hatfield, A.K., Maihle, N., Michalak, J.C., Kuross, S.A., Kugler, J.W., Lafky, J.M., Ingle, J.N. Ann. Oncol. (2002) [Pubmed]
  39. Anti-cancer treatment - 12th International Congress. 4-7 February 2002, Paris, France. Perez, E.A. IDrugs (2002) [Pubmed]
  40. Doxorubicin and paclitaxel in the treatment of advanced breast cancer: efficacy and cardiac considerations. Perez, E.A. Cancer Invest. (2001) [Pubmed]
  41. The role of adjuvant monoclonal antibody therapy for breast cancer: rationale and new studies. Perez, E.A. Curr. Oncol. Rep (2001) [Pubmed]
  42. Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. Perez, E.A., Vogel, C.L., Irwin, D.H., Kirshner, J.J., Patel, R. J. Clin. Oncol. (2001) [Pubmed]
  43. Rationale and design of a phase III trial of adjuvant sequential epirubicin/ cyclophosphamide and taxane versus concurrent epirubicin/taxane in operable node-positive breast cancer. Perez, E.A. Clin. Breast Cancer (2000) [Pubmed]
  44. Antiemetic therapy for high-dose chemotherapy with transplantation: report of a retrospective analysis of a 5-HT(3) regimen and literature review. Perez, E.A., Tiemeier, T., Solberg, L.A. Support. Care. Cancer (1999) [Pubmed]
  45. 5-HT3 antiemetic therapy for patients with breast cancer. Perez, E.A. Breast Cancer Res. Treat. (1999) [Pubmed]
  46. Paclitaxel in Breast Cancer. Perez, E.A. Oncologist (1998) [Pubmed]
  47. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. Perez, E.A., Hesketh, P., Sandbach, J., Reeves, J., Chawla, S., Markman, M., Hainsworth, J., Bushnell, W., Friedman, C. J. Clin. Oncol. (1998) [Pubmed]
 
WikiGenes - Universities